"Rapid Generation of Gene-Edited Animal Models Bypassing Traditional Breeding," stood out among thousands of high-quality national entries and ultimately won the Top Award in the finals, earning prestigious recognition as a "disruptive technology."

MingCeler Biotech, a pioneer in tetraploid complementation technology, has successfully closed its Pre-A+ funding round with ECC Capital as the lead investor. This follows the company’s earlier angel and Pre-A rounds, bringing its total funding to tens of millions of yuan to date.